Celltrion Pharm (068760) Fundamentals 2026 — P/E 41.6x, Revenue Analysis | SniperIQ
Celltrion Pharm (068760) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩1.68T, trading at ₩38000.00 on the KOE. This SniperIQ fundamentals page covers Celltrion Pharm's valuation (P/E 41.6x, P/B 3.9x), profitability (net margin 7.2%), revenue (₩536.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Celltrion Pharm's market cap?
Celltrion Pharm (068760) has a market capitalization of approximately ₩1.68T, trading at ₩38000.00 on the KOE. Market cap moves with the live share price.
What is Celltrion Pharm's P/E ratio?
Celltrion Pharm's trailing twelve-month P/E ratio is 41.6x, with a price-to-book (P/B) of 3.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Celltrion Pharm?
Celltrion Pharm runs a net profit margin of 7.2%, a gross margin of 29.8%, and an operating margin of 10.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Celltrion Pharm generate?
Celltrion Pharm reported revenue of ₩536.4B for fiscal year 2025, with net income of ₩38.8B and earnings per share (EPS) of 892.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Celltrion Pharm pay a dividend?
Celltrion Pharm offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Celltrion Pharm financially healthy?
Celltrion Pharm carries a debt-to-equity ratio of 0.37x and a current ratio of 1.65x, with a market beta of 0.96. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Celltrion Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Celltrion Pharm (068760) the key facts are: market cap ₩1.68T, P/E 41.6x, revenue ₩536.4B, 52-week range 37800-78300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Celltrion Pharm's full fundamentals live
Get Celltrion Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.